Oxysterol signaling links cholesterol metabolism and inflammation via the liver X receptor in macrophages

Molecular Aspects of Medicine

Volumn 30, Issue 3, 2009, Pages 134-152

  Töröcsik, Dániel ^a   Szanto, Attila ^a   Nagy, László ^a,b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Atherosclerosis; Inflammation; LXR; Macrophage; Nuclear receptor; Oxysterol; PPAR ; Transcription network

Indexed keywords

CELL NUCLEUS RECEPTOR; CHOLESTEROL; LIGAND; LIPID; LIVER X RECEPTOR; OXYSTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ATHEROSCLEROSIS; CHOLESTEROL METABOLISM; CHOLESTEROL TRANSPORT; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; HUMAN; INFLAMMATION; MACROPHAGE; MACROPHAGE FUNCTION; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; CHOLESTEROL; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; LIPID METABOLISM; MACROPHAGES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 67349215164     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mam.2009.02.002     Document Type: Review

References (204)

1. Akiyama T.E., Sakai S., Lambert G., Nicol C.J., Matsusue K., Pimprale S., Lee Y.H., Ricote M., Glass C.K., Brewer Jr. H.B., and Gonzalez F.J. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol. Cell Biol. 22 (2002) 2607-2619
2. Albers M., Blume B., Schlueter T., Wright M.B., Kober I., Kremoser C., Deuschle U., and Koegl M. A novel principle for partial agonism of liver X receptor ligands. Competitive recruitment of activators and repressors. J. Biol. Chem. 281 (2006) 4920-4930
3. Alberti S., Schuster G., Parini P., Feltkamp D., Diczfalusy U., Rudling M., Angelin B., Björkhem I., Pettersson S., and Gustafsson J.A. Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRβ-deficient mice. J. Clin. Invest. 107 (2001) 565-573
4. Andersson S., Davis D.L., Dahlback H., Jornvall H., and Russell D.W. Cloning, structure, and expression of the mitochondrial cytochrome P-450 sterol 26-hydroxylase, a bile acid biosynthetic enzyme. J. Biol. Chem. 264 (1989) 8222-8229
5. Apfel R., Benbrook D., Lernhardt E., Ortiz M.A., Salbert G., and Pfahl M. A novel orphan receptor specific for a subset of thyroid hormone-responsive elements and its interaction with the retinoid/thyroid hormone receptor subfamily. Mol. Cell Biol. 14 (1994) 7025-7035
6. Arai S., Shelton J.M., Chen M., Bradley M.N., Castrillo A., Bookout A.L., Mak P.A., Edwards P.A., Mangelsdorf D.J., Tontonoz P., and Miyazaki T. A role for the apoptosis inhibitory factor AIM/Spα/Api6 in atherosclerosis development. Cell Metab. 1 (2005) 201-213
7. Argmann C.A., Edwards J.Y., Sawyez C.G., O'Neil C.H., Hegele R.A., Pickering J.G., and Huff M.W. Regulation of macrophage cholesterol efflux through hydroxymethylglutaryl-CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol efflux. J. Biol. Chem. 280 (2005) 22212-22221
8. Babiker A., Andersson O., Lindblom D., van der Linden J., Wiklund B., Lutjohann D., Diczfalusy U., and Björkhem I. Elimination of cholesterol as cholestenoic acid in human lung by sterol 27-hydroxylase: evidence that most of this steroid in the circulation is of pulmonary origin. J. Lipid Res. 40 (1999) 1417-1425
9. Barak Y., Nelson M.C., Ong E.S., Jones Y.Z., Ruiz-Lozano P., Chien K.R., Koder A., and Evans R.M. PPARγ is required for placental, cardiac, and adipose tissue development. Mol. Cell 4 (1999) 585-595
10. Bensinger S.J., Bradley M.N., Joseph S.B., Zelcer N., Janssen E.M., Hausner M.A., Shih R., Parks J.S., Edwards P.A., Jamieson B.D., and Tontonoz P. LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell 134 (2008) 97-111
11. Beyea M.M., Heslop C.L., Sawyez C.G., Edwards J.Y., Markle J.G., Hegele R.A., and Huff M.W. Selective up-regulation of LXR-regulated genes ABCA1, ABCG1, and APOE in macrophages through increased endogenous synthesis of 24(S), 25-epoxycholesterol. J. Biol. Chem. 282 (2007) 5207-5216
12. Björkhem I. Do oxysterols control cholesterol homeostasis?. J. Clin. Invest. 110 (2002) 725-730
13. Björkhem I., and Leitersdorf E. Sterol 27-hydroxylase deficiency: a rare cause of xanthomas in normocholesterolemic humans. Trends Endocrinol. Metab. 11 (2000) 180-183
14. Björkhem I., Andersson O., Diczfalusy U., Sevastik B., Xiu R.J., Duan C., and Lund E. Atherosclerosis and sterol 27-hydroxylase: evidence for a role of this enzyme in elimination of cholesterol from human macrophages. Proc. Natl. Acad. Sci. USA 91 (1994) 8592-8596
15. Bodzioch M., Orsó E., Klucken J., Langmann T., Böttcher A., Diederich W., Drobnik W., Barlage S., Büchler C., Porsch-Ozcürümez M., Kaminski W.E., Hahmann H.W., Oette K., Rothe G., Aslanidis C., Lackner K.J., and Schmitz G. The gene encoding ATP-binding cassette transporter 1 is mutated in Tangier disease. Nat. Genet. 22 (1999) 347-351
16. Bookout A.L., Jeong Y., Downes M., Yu R.T., Evans R.M., and Mangelsdorf D.J. Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network. Cell 126 (2006) 789-799
17. Bradley M.N., Hong C., Chen M., Joseph S.B., Wilpitz D.C., Wang X., Lusis A.J., Collins A., Hseuh W.A., Collins J.L., Tangirala R.K., and Tontonoz P. Ligand activation of LXRβ reverses atherosclerosis and cellular cholesterol overload in mice lacking LXRα and apoE. J. Clin. Invest. 117 (2007) 2337-2346
18. Bramlett K.S., Houck K.A., Borchert K.M., Dowless M.S., Kulanthaivel P., Zhang Y., Beyer T.P., Schmidt R., Thomas J.S., Michael L.F., Barr R., Montrose C., Eacho P.I., Cao G., and Burris T.P. A natural product ligand of the oxysterol receptor, liver X receptor. J. Pharmacol. Exp. Ther. 307 (2003) 291-296
19. Brendel C., Schoonjans K., Botrugno O.A., Treuter E., and Auwerx J. The small heterodimer partner interacts with the liver X receptor alpha and represses its transcriptional activity. Mol. Endocrinol. 16 (2002) 2065-2076
20. Bretillon L., Diczfalusy U., Björkhem I., Maire M.A., Martine L., Joffre C., Acar N., Bron A., and Creuzot-Garcher C. Cholesterol-24S-hydroxylase (CYP46A1) is specifically expressed in neurons of the neural retina. Curr. Eye Res. 32 (2007) 361-366
21. Brooks C.J., Steel G., Gilbert J.D., and Harland W.A. Lipids of human atheroma. 4. Characterisation of a new group of polar sterol esters from human atherosclerotic plaques. Atherosclerosis 13 (1971) 223-237
22. Brooks-Wilson A., Marcil M., Clee S.M., Zhang L.H., Roomp K., van Dam M., Yu L., Brewer C., Collins J.A., Molhuizen H.O., Loubser O., Ouelette B.F., Fichter K., Ashbourne-Excoffon K.J., Sensen C.W., Scherer S., Mott S., Denis M., Martindale D., Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J., Genest Jr. J., and Hayden M.R. Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat. Genet. 22 (1999) 336-345
23. Brun R.P., Tontonoz P., Forman B.M., Ellis R., Chen J., Evans R.M., and Spiegelman B.M. Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev. 10 (1996) 974-984
24. Brzozowski A.M., Pike A.C., Dauter Z., Hubbard R.E., Bonn T., Engstrom O., Ohman L., Greene G.L., Gustafsson J.A., and Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389 (1997) 753-758
25. Cali J.J., and Russell D.W. Characterization of human sterol 27-hydroxylase. A mitochondrial cytochrome P-450 that catalyzes multiple oxidation reaction in bile acid biosynthesis. J. Biol. Chem. 266 (1991) 7774-7778
26. Cali J.J., Hsieh C.L., Francke U., and Russell D.W. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. J. Biol. Chem. 266 (1991) 7779-7783
27. Cao G., Beyer T.P., Yang X.P., Schmidt R.J., Zhang Y., Bensch W.R., Kauffman R.F., Gao H., Ryan T.P., Liang Y., Eacho P.I., and Jiang X.C. Phospholipid transfer protein is regulated by liver X receptors in vivo. J. Biol. Chem. 277 (2002) 39561-39565
28. Castrillo A., Joseph S.B., Vaidya S.A., Haberland M., Fogelman A.M., Cheng G., and Tontonoz P. Crosstalk between LXR and Toll-like receptor signaling mediates bacterial and viral antagonism of cholesterol metabolism. Mol. Cell 12 (2003) 805-816
29. Castrillo A., Joseph S.B., Marathe C., Mangelsdorf D.J., and Tontonoz P. Liver X receptor-dependent repression of matrix metalloproteinase-9 expression in macrophages. J. Biol. Chem. 278 (2003) 10443-10449
30. Chawla A., Repa J.J., Evans R.M., and Mangelsdorf D.J. Nuclear receptors and lipid physiology: opening the X-files. Science 294 (2001) 1866-1870
31. Chawla A., Boisvert W.A., Lee C.H., Laffitte B.A., Barak Y., Joseph S.B., Liao D., Nagy L., Edwards P.A., Curtiss L.K., Evans R.M., and Tontonoz P. A PPARγ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol. Cell 7 (2001) 161-171
32. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7 (2001) 48-52
33. Chen Z., Ishibashi S., Perrey S., Osuga J., Gotoda T., Kitamine T., Tamura Y., Okazaki H., Yahagi N., Iizuka Y., Shionoiri F., Ohashi K., Harada K., Shimano H., Nagai R., and Yamada N. Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 372-377
34. Chen M., Beaven S., and Tontonoz P. Identification and characterization of two alternatively spliced transcript variants of human liver X receptorα. J. Lipid Res. 46 (2005) 2570-2579
35. Chen M., Bradley M.N., Beaven S.W., and Tontonoz P. Phosphorylation of the liver X receptors. FEBS Lett. 580 (2006) 4835-4841
36. Chen W., Chen G., Head D.L., Mangelsdorf D.J., and Russell D.W. Enzymatic reduction of oxysterols impairs LXR signaling in cultured cells and the livers of mice. Cell Metab. 5 (2007) 73-79
37. Chiang J.Y., Kimmel R., and Stroup D. Regulation of cholesterol 7α-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRα). Gene 262 (2001) 257-265
38. Chisholm J.W., Hong J., Mills S.A., and Lawn R.M. The LXR ligand T0901317 induces severe lipogenesis in the db/db diabetic mouse. J. Lipid Res. 44 (2003) 2039-2048
39. Claudel T., Leibowitz M.D., Fiévet C., Tailleux A., Wagner B., Repa J.J., Torpier G., Lobaccaro J.M., Paterniti J.R., Mangelsdorf D.J., Heyman R.A., and Auwerx J. Reduction of atherosclerosis in apolipoprotein E knockout mice by activation of the retinoid X receptor. Proc. Natl. Acad. Sci. USA 98 (2001) 2610-2615
40. Collins J.L., Fivush A.M., Watson M.A., Galardi C.M., Lewis M.C., Moore L.B., Parks D.J., Wilson J.G., Tippin T.K., Binz J.G., Plunket K.D., Morgan D.G., Beaudet E.J., Whitney K.D., Kliewer S.A., and Willson T.M. Identification of a nonsteroidal liver X receptor agonist through parallel array synthesis of tertiary amines. J. Med. Chem. 45 (2002) 1963-1966
41. Costet P., Luo Y., Wang N., and Tall A.R. Sterol-dependent transactivation of the ABC1 promoter by the liver X receptor/retinoid X receptor. J. Biol. Chem. 275 (2000) 28240-28245
42. Crisby M., Nilsson J., Kostulas V., Björkhem I., and Diczfalusy U. Localization of sterol 27-hydroxylase immuno-reactivity in human atherosclerotic plaques. Biochim. Biophys. Acta 1344 (1997) 278-285
43. DeBose-Boyd R.A., Ou J., Goldstein J.L., and Brown M.S. Expression of sterol regulatory element-binding protein 1c (SREBP-1c) mRNA in rat hepatoma cells requires endogenous LXR ligands. Proc. Natl. Acad. Sci. USA 98 (2001) 1477-1482
44. Denechaud P.D., Bossard P., Lobaccaro J.M., Millatt L., Staels B., Girard J., and Postic C. ChREBP, but not LXRs, is required for the induction of glucose-regulated genes in mouse liver. J. Clin. Invest. 118 (2008) 956-964
45. DuSell C.D., Umetani M., Shaul P.W., Mangelsdorf D.J., and McDonnell D.P. 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol. Endocrinol. 22 (2008) 65-77
46. Engel T., Lorkowski S., Lueken A., Rust S., Schluter B., Berger G., Cullen P., and Assmann G. The human ABCG4 gene is regulated by oxysterols and retinoids in monocyte-derived macrophages. Biochem. Biophys. Res. Commun. 288 (2001) 483-488
47. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science 240 (1988) 889-895
48. Fontaine C., Rigamonti E., Nohara A., Gervois P., Teissier E., Fruchart J.C., Staels B., and Chinetti-Gbaguidi G. Liver X receptor activation potentiates the lipopolysaccharide response in human macrophages. Circ. Res. 101 (2007) 40-49
49. Forman B.M., Tontonoz P., Chen J., Brun R.P., Spiegelman B.M., and Evans R.M. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 83 (1995) 803-812
50. Fowler A.J., Sheu M.Y., Schmuth M., Kao J., Fluhr J.W., Rhein L., Collins J.L., Willson T.M., Mangelsdorf D.J., Elias P.M., and Feingold K.R. Liver X receptor activators display anti-inflammatory activity in irritant and allergic contact dermatitis models: liver-X-receptor-specific inhibition of inflammation and primary cytokine production. J. Invest. Dermatol. 120 (2003) 246-255
51. Friedman A.D. Transcriptional regulation of granulocyte and monocyte development. Oncogene 21 (2002) 3377-3390
52. Fu X., Menke J.G., Chen Y., Zhou G., MacNaul K.L., Wright S.D., Sparrow C.P., and Lund E.G. 27-Hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J. Biol. Chem. 276 (2001) 38378-38387
53. Geyeregger R., Zeyda M., Bauer W., Kriehuber E., Saemann M.D., Zlabinger G.J., Maurer D., and Stulnig T.M. Liver X receptors regulate dendritic cell phenotype and function through blocked induction of the actin-bundling protein fascin. Blood 109 (2007) 4288-4295
54. Ghisletti S., Huang W., Ogawa S., Pascual G., Lin M.E., Willson T.M., Rosenfeld M.G., and Glass C.K. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARγ. Mol. Cell 25 (2007) 57-70
55. Glass C.K., and Witztum J.L. Atherosclerosis. The road ahead. Cell 104 (2001) 503-516
56. Grefhorst A., Elzinga B.M., Voshol P.J., Plosch T., Kok T., Bloks V.W., van der Sluijs F.H., Havekes L.M., Romijn J.A., Verkade H.J., and Kuipers F. Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles. J. Biol. Chem. 277 (2002) 34182-34190
57. Gresham G.A., and Howard A.N. The histogenesis of the atherosclerotic "fatty streak". J. Atheroscler. Res. 1 (1961) 413-416
58. Haller H. Epidermiology and associated risk factors of hyperlipoproteinemia. Z. Gesamte Inn. Med. 32 (1977) 124-128
59. Harland W.A., Gilbert J.D., Steel G., and Brooks C.J. Lipids of human atheroma. 5. The occurrence of a new group of polar sterol esters in various stages of human atherosclerosis. Atherosclerosis 13 (1971) 239-246
60. Herath K., Jayasuriya H., Ondeyka J.G., Guan Z., Borris R.P., Stijfhoorn E., Stevenson D., Wang J., Sharma N., Macnaul K., Menke J.G., Ali A., Schulman M.J., and Singh S.B. Guttiferone I, a new prenylated benzophenone from Garcinia humilis as a liver X receptor ligand. J. Nat. Prod. 68 (2005) 617-619
61. Herath K.B., Jayasuriya H., Guan Z., Schulman M., Ruby C., Sharma N., MacNaul K., Menke J.G., Kodali S., Galgoci A., Wang J., and Singh S.B. Anthrabenzoxocinones from Streptomyces sp. as liver X receptor ligands and antibacterial agents. J. Nat. Prod. 68 (2005) 1437-1440
62. Herzog B., Hallberg M., Seth A., Woods A., White R., and Parker M.G. The nuclear receptor cofactor, receptor-interacting protein 140, is required for the regulation of hepatic lipid and glucose metabolism by liver X receptor. Mol. Endocrinol. 21 (2007) 2687-2697
63. Honda A., Salen G., Matsuzaki Y., Batta A.K., Xu G., Leitersdorf E., Tint G.S., Erickson S.K., Tanaka N., and Shefer S. Differences in hepatic levels of intermediates in bile acid biosynthesis between CYP27(-/-) mice and CTX. J. Lipid Res. 42 (2001) 291-300
64. Houck K.A., Borchert K.M., Hepler C.D., Thomas J.S., Bramlett K.S., Michael L.F., and Burris T.P. T0901317 is a dual LXR/FXR agonist. Mol. Genet. Metab. 83 (2004) 184-187
65. Hu X., Li S., Wu J., Xia C., and Lala D.S. Liver X receptors interact with corepressors to regulate gene expression. Mol. Endocrinol. 17 (2003) 1019-1026
66. Huang T.H., Razmovski-Naumovski V., Salam N.K., Duke R.K., Tran V.H., Duke C.C., and Roufogalis B.D. A novel LXR-alpha activator identified from the natural product Gynostemma pentaphyllum. Biochem. Pharmacol. 70 (2005) 1298-1308
67. Hulten L.M., Lindmark H., Diczfalusy U., Björkhem I., Ottosson M., Liu Y., Bondjers G., and Wiklund O. Oxysterols present in atherosclerotic tissue decrease the expression of lipoprotein lipase messenger RNA in human monocyte-derived macrophages. J. Clin. Invest. 97 (1996) 461-468
68. Huuskonen J., Fielding P.E., and Fielding C.J. Role of p160 coactivator complex in the activation of liver X receptor. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 703-708
69. Huuskonen J., Vishnu M., Fielding P.E., and Fielding C.J. Activation of ATP-binding cassette transporter A1 transcription by chromatin remodeling complex. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1180-1185
70. Ishimoto K., Tachibana K., Sumitomo M., Omote S., Hanano I., Yamasaki D., Watanabe Y., Tanaka T., Hamakubo T., Sakai J., Kodama T., and Doi T. Identification of human low-density lipoprotein receptor as a novel target gene regulated by liver X receptor α. FEBS Lett. 580 (2006) 4929-4933
71. Itoh T., and Yamamoto K. Peroxisome proliferator activated receptor γ and oxidized docosahexaenoic acids as new class of ligand. Naunyn Schmiedebergs Arch. Pharmacol. 377 (2008) 541-547
72. Janowski B.A., Willy P.J., Devi T.R., Falck J.R., and Mangelsdorf D.J. An oxysterol signalling pathway mediated by the nuclear receptor LXRα. Nature 383 (1996) 728-731
73. Janowski B.A., Grogan M.J., Jones S.A., Wisely G.B., Kliewer S.A., Corey E.J., and Mangelsdorf D.J. Structural requirements of ligands for the oxysterol liver X receptors LXRα and LXRβ. Proc. Natl. Acad. Sci. USA 96 (1999) 266-271
74. Jayasuriya H., Herath K.B., Ondeyka J.G., Guan Z., Borris R.P., Tiwari S., de Jong W., Chavez F., Moss J., Stevenson D.W., Beck H.T., Slattery M., Zamora N., Schulman M., Ali A., Sharma N., MacNaul K., Hayes N., Menk J.G., and Singh S.B. Diterpenoid, steroid, and triterpenoid agonists of liver X receptors from diversified terrestrial plants and marine sources. J. Nat. Prod. 68 (2005) 1247-1252
75. Jaye M.C., Krawiec J.A., Campobasso N., Smallwood A., Qiu C., Lu Q., Kerrigan J.J., De Los Frailes Alvaro M., Laffitte B., Liu W.S., Marino Jr. J.P., Meyer C.R., Nichols J.A., Parks D.J., Perez P., Sarov-Blat L., Seepersaud S.D., Steplewski K.M., Thompson S.K., Wang P., Watson M.A., Webb C.L., Haigh D., Caravella J.A., Macphee C.H., Willson T.M., and Collins J.L. Discovery of substituted maleimides as liver X receptor agonists and determination of a ligand-bound crystal structure. J. Med. Chem. 48 (2005) 5419-5422
76. Joseph S.B., Laffitte B.A., Patel P.H., Watson M.A., Matsukuma K.E., Walczak R., Collins J.L., Osborne T.F., and Tontonoz P. Direct and indirect mechanisms for regulation of fatty acid synthase gene expression by liver X receptors. J. Biol. Chem. 277 (2002) 11019-11025
77. Joseph S.B., McKilligin E., Pei L., Watson M.A., Collins A.R., Laffitte B.A., Chen M., Noh G., Goodman J., Hagger G.N., Tran J., Tippin T.K., Wang X., Lusis A.J., Hsueh W.A., Law R.E., Collins J.L., Willso T.M., and Tontonoz P. Synthetic LXR ligand inhibits the development of atherosclerosis in mice. Proc. Natl. Acad. Sci. USA 99 (2002) 7604-7609
78. Joseph S.B., Castrillo A., Laffitte B.A., Mangelsdorf D.J., and Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat. Med. 9 (2003) 213-219
79. Joseph S.B., Bradley M.N., Castrillo A., Bruhn K.W., Mak P.A., Pei L., Hogenesch J., O'connell R.M., Cheng G., Saez E., Miller J.F., and Tontonoz P. LXR-dependent gene expression is important for macrophage survival and the innate immune response. Cell 119 (2004) 299-309
80. Kaneko E., Matsuda M., Yamada Y., Tachibana Y., Shimomura I., and Makishima M. Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist. J. Biol. Chem. 278 (2003) 36091-36098
81. Kennedy M.A., Venkateswaran A., Tarr P.T., Xenarios I., Kudoh J., Shimizu N., and Edwards P.A. Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J. Biol. Chem. 276 (2001) 39438-39447
82. Kersten S., Desvergne B., and Wahli W. Roles of PPARs in health and disease. Nature 405 (2000) 421-424
83. Kliewer S.A., Lenhard J.M., Willson T.M., Patel I., Morris D.C., and Lehmann J.M. A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation. Cell 83 (1995) 813-819
84. Kliewer S.A., Sundseth S.S., Jones S.A., Brown P.J., Wisely G.B., Koble C.S., Devchand P., Wahli W., Willson T.M., Lenhard J.M., and Lehmann J.M. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc. Natl. Acad. Sci. USA 94 (1997) 4318-4323
85. Kohro T., Nakajima T., Wada Y., Sugiyama A., Ishii M., Tsutsumi S., Aburatani H., Imoto I., Inazawa J., Hamakubo T., Kodama T., and Emi M. Genomic structure and mapping of human orphan receptor LXRα: upregulation of LXRa mRNA during monocyte to macrophage differentiation. J. Atheroscler. Thromb. 7 (2000) 145-151
86. Kratzer, A., Buchebner, M., Pfeifer, T., Becker, T.M., Uray, G., Miyazaki, M., Miyazaki-Anzai, S., Ebner, B., Chandak, P.G., Kadam, R.S., Calayir, E., Rathke, N., Ahammer, H., Radovic, B., Trauner, M., Hoefler, G., Kompella, U.B., Fauler, G., Levi, M., Levak-Frank, S., Kostner, G.M., Kratky, D., 2008. Synthetic LXR agonist attenuates plaque formation in apoE-deficient mice without inducing liver steatosis and hypertriglyceridemia. J. Lipid Res., Epub (September 23).
87. Krey G., Braissant O., L'Horset F., Kalkhoven E., Perroud M., Parker M.G., and Wahli W. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol. Endocrinol. 11 (1997) 779-791
88. Kubota N., Terauchi Y., Miki H., Tamemoto H., Yamauchi T., Komeda K., Satoh S., Nakano R., Ishii C., Sugiyama T., Eto K., Tsubamoto Y., Okuno A., Murakami K., Sekihara H., Hasegawa G., Naito M., Toyoshima Y., Tanaka S., Shiota K., Kitamura T., Fujita T., Ezaki O., Aizawa S., Nagai R., Tobe K., Kimura S., and Kadowaki T. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell 4 (1999) 597-609
89. Laffitte B.A., Repa J.J., Joseph S.B., Wilpitz D.C., Kast H.R., Mangelsdorf D.J., and Tontonoz P. LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc. Natl. Acad. Sci. USA 98 (2001) 507-512
90. Laffitte B.A., Joseph S.B., Walczak R., Pei L., Wilpitz D.C., Collins J.L., and Tontonoz P. Autoregulation of the human liver X receptor α promoter. Mol. Cell Biol. 21 (2001) 7558-7568
91. Laffitte B.A., Joseph S.B., Chen M., Castrillo A., Repa J., Wilpitz D., Mangelsdorf D., and Tontonoz P. The phospholipid transfer protein gene is a liver X receptor target expressed by macrophages in atherosclerotic lesions. Mol. Cell Biol. 23 (2003) 2182-2191
92. Laue L., Kawai S., Brandon D.D., Brightwell D., Barnes K., Knazek R.A., Loriaux D.L., and Chrousos G.P. Receptor-mediated effects of glucocorticoids on inflammation: enhancement of the inflammatory response with a glucocorticoid antagonist. J. Steroid Biochem. 29 (1988) 591-598
93. Lee S., Lee J., Lee S.K., and Lee J.W. Activating signal cointegrator-2 is an essential adaptor to recruit histone H3 lysine 4 methyltransferases MLL3 and MLL4 to the liver X receptors. Mol. Endocrinol. 22 (2008) 1312-1319
94. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., and Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPARγ). J. Biol. Chem. 270 (1995) 12953-12956
95. Lehmann J.M., Kliewer S.A., Moore L.B., Smith-Oliver T.A., Oliver B.B., Su J.L., Sundseth S.S., Winegar D.A., Blanchard D.E., Spencer T.A., and Willson T.M. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272 (1997) 3137-3140
96. Levin N., Bischoff E.D., Daige C.L., Thomas D., Vu C.T., Heyman R.A., Tangirala R.K., and Schulman I.G. Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 135-142
97. Li A.C., Brown K.K., Silvestre M.J., Willson T.M., Palinski W., and Glass C.K. Peroxisome proliferator-activated receptor γ ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106 (2000) 523-531
98. Li Y., Bolten C., Bhat B.G., Woodring-Dietz J., Li S., Prayaga S.K., Xia C., and Lala D.S. Induction of human liver X receptor α gene expression via an autoregulatory loop mechanism. Mol. Endocrinol. 16 (2002) 506-514
99. Li X., Zhang S., Blander G., Tse J.G., Krieger M., and Guarente L. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol. Cell 28 (2007) 91-106
100. Lin R.J., Egan D.A., and Evans R.M. Molecular genetics of acute promyelocytic leukemia. Trends Genet. 15 (1999) 179-184
101. Lowell B.B. PPARγ: an essential regulator of adipogenesis and modulator of fat cell function. Cell 99 (1999) 239-242
102. Lukyanenko Y.O., Chen J.J., and Hutson J.C. Production of 25-hydroxycholesterol by testicular macrophages and its effects on Leydig cells. Biol. Reprod. 64 (2001) 790-796
103. Lund E.G., Guileyardo J.M., and Russell D.W. CDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc. Natl. Acad. Sci. USA 96 (1999) 7238-7243
104. Lund E.G., Xie C., Kotti T., Turley S.D., Dietschy J.M., and Russell D.W. Knockout of the cholesterol 24-hydroxylase gene in mice reveals a brain-specific mechanism of cholesterol turnover. J. Biol. Chem. 278 (2003) 22980-22988
105. Luo Y., and Tall A.R. Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. J. Clin. Invest. 105 (2000) 513-520
106. Lusis A.J. Atherosclerosis. Nature 407 (2000) 233-241
107. Majdalawieh A., Zhang L., Fuki I.V., Rader D.J., and Ro H.S. Adipocyte enhancer-binding protein 1 is a potential novel atherogenic factor involved in macrophage cholesterol homeostasis and inflammation. Proc. Natl. Acad. Sci. USA 103 (2006) 2346-2351
108. Mak P.A., Kast-Woelbern H.R., Anisfeld A.M., and Edwards P.A. Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. J. Lipid Res. 43 (2002) 2037-2041
109. Mak P.A., Laffitte B.A., Desrumaux C., Joseph S.B., Curtiss L.K., Mangelsdorf D.J., Tontonoz P., and Edwards P.A. Regulated expression of the apolipoprotein E/C-I/C-IV/C-II gene cluster in murine and human macrophages. A critical role for nuclear liver X receptors α and β. J. Biol. Chem. 277 (2002) 31900-31908
110. Malerod L., Juvet L.K., Hanssen-Bauer A., Eskild W., and Berg T. Oxysterol-activated LXRα/RXR induces hSR-BI-promoter activity in hepatoma cells and preadipocytes. Biochem. Biophys. Res. Commun. 299 (2002) 916-923
111. Mannucci E., Monami M., Lamanna C., Gensini G.F., and Marchionni N. Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials. Diabetes Obes. Metab. 10 (2008) 1221-1238
112. Marx N., Bourcier T., Sukhova G.K., Libby P., and Plutzky J. PPARγ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARγ as a potential mediator in vascular disease. Arterioscler. Thromb. Vasc. Biol. 19 (1999) 546-551
113. Mast N., White M.A., Björkhem I., Johnson E.F., Stout C.D., and Pikuleva I.A. Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain. Proc. Natl. Acad. Sci. USA 105 (2008) 9546-9551
114. Mitro N., Mak P.A., Vargas L., Godio C., Hampton E., Molteni V., Kreusch A., and Saez E. The nuclear receptor LXR is a glucose sensor. Nature 445 (2007) 219-223
115. Mitro N., Vargas L., Romeo R., Koder A., and Saez E. T0901317 is a potent PXR ligand: implications for the biology ascribed to LXR. FEBS Lett. 581 (2007) 1721-1726
116. Moghadasian M.H., Salen G., Frohlich J.J., and Scudamore C.H. Cerebrotendinous xanthomatosis: a rare disease with diverse manifestations. Arch. Neurol. 59 (2002) 527-529
117. Molteni V., Li X., Nabakka J., Liang F., Wityak J., Koder A., Vargas L., Romeo R., Mitro N., Mak P.A., Seidel H.M., Haslam J.A., Chow D., Tuntland T., Spalding T.A., Brock A., Bradley M., Castrillo A., Tontonoz P., and Saez E. N-Acylthiadiazolines, a new class of liver X receptor agonists with selectivity for LXRβ. J. Med. Chem. 50 (2007) 4255-4259
118. Moore K.J., Rosen E.D., Fitzgerald M.L., Randow F., Andersson L.P., Altshuler D., Milstone D.S., Mortensen R.M., Spiegelman B.M., and Freeman M.W. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat. Med. 7 (2001) 41-47
119. Nagy L., and Schwabe J.W. Mechanism of the nuclear receptor molecular switch. Trends Biochem. Sci. 29 (2004) 317-324
120. Nagy L., Tontonoz P., Alvarez J.G., Chen H., and Evans R.M. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARγ. Cell 93 (1998) 229-240
121. Nagy L., Kao H.Y., Love J.D., Li C., Banayo E., Gooch J.T., Krishna V., Chatterjee K., Evans R.M., and Schwabe J.W. Mechanism of corepressor binding and release from nuclear hormone receptors. Genes Dev. 13 (1999) 3209-3216
122. Navab M., Berliner J.A., Watson A.D., Hama S.Y., Territo M.C., Lusis A.J., Shih D.M., Van Lenten B.J., Frank J.S., Demer L.L., Edwards P.A., and Fogelman A.M. The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff memorial lecture. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 831-842
123. Nelson J.A., Steckbeck S.R., and Spencer T.A. Biosynthesis of 24,25-epoxycholesterol from squalene 2,3,22,23-dioxide. J. Biol. Chem. 256 (1981) 1067-1068
124. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 356 (2007) 2457-2471
125. Nissen S.E., Nicholls S.J., Wolski K., Nesto R., Kupfer S., Perez A., Jure H., De Larochellière R., Staniloae C.S., Mavromatis K., Saw J., Hu B., Lincoff A.M., Tuzcu E.M., and PERISCOPE Investigators. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 299 (2008) 1561-1573
126. Nolte R.T., Wisely G.B., Westin S., Cobb J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., and Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 395 (1998) 137-143
127. Oberkofler H., Schraml E., Krempler F., and Patsch W. Potentiation of liver X receptor transcriptional activity by peroxisome-proliferator-activated receptor γ co-activator 1α. Biochem. J. 371 (2003) 89-96
128. Obinata H., Hattori T., Nakane S., Tatei K., and Izumi T. Identification of 9-hydroxyoctadecadienoic acid and other oxidized free fatty acids as ligands of the G protein-coupled receptor G2A. J. Biol. Chem. 280 (2005) 40676-40683
129. Ondeyka J.G., Jayasuriya H., Herath K.B., Guan Z., Schulman M., Collado J., Dombrowski A.W., Kwon S.S., McCallum C., Sharma N., MacNaul K., Hayes N., Menke J.G., and Singh S.B. Steroidal and triterpenoidal fungal metabolites as ligands of liver X receptors. J. Antibiot. (Tokyo) 58 (2005) 559-565
130. Ouimet M., Wang M.D., Cadotte N., Ho K., and Marcel Y.L. Epoxycholesterol impairs cholesteryl ester hydrolysis in macrophage foam cells, resulting in decreased cholesterol efflux. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 1144-1150
131. Peet D.J., Turley S.D., Ma W., Janowski B.A., Lobaccaro J.M., Hammer R.E., and Mangelsdorf D.J. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXRα. Cell 93 (1998) 693-704
132. Peng D., Hiipakka R.A., Dai Q., Guo J., Reardon C.A., Getz G.S., and Liao S. Antiatherosclerotic effects of a novel synthetic tissue-selective steroidal liver X receptor agonist in low-density lipoprotein receptor-deficient mice. J. Pharmacol. Exp. Ther. 327 (2008) 332-342
133. Phelan C.A., Weaver J.M., Steger D.J., Joshi S., Maslany J.T., Collins J.L., Zuercher W.J., Willson T.M., Walker M., Jaye M., and Lazar M.A. Selective partial agonism of liver X receptor α is related to differential corepressor recruitment. Mol. Endocrinol. 22 (2008) 2241-2249
134. Pikuleva I.A., Babiker A., Waterman M.R., and Björkhem I. Activities of recombinant human cytochrome P450c27 (CYP27) which produce intermediates of alternative bile acid biosynthetic pathways. J. Biol. Chem. 273 (1998) 18153-18160
135. 2: endogenous PPARγ ligand or minor eicosanoid degradation product?. J. Clin. Invest. 112 (2003) 828-830
136. Qiu G., and Hill J.S. Atorvastatin inhibits ABCA1 expression and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway. J. Cardiovasc. Pharmacol. 51 (2008) 388-395
137. Quinet E.M., Savio D.A., Halpern A.R., Chen L., Miller C.P., and Nambi P. Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor. J. Lipid Res. 45 (2004) 1929-1942
138. Quinn M.T., Parthasarathy S., Fong L.G., and Steinberg D. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Natl. Acad. Sci. USA 84 (1987) 2995-2998
139. Quinn C.M., Jessup W., Wong J., Kritharides L., and Brown A.J. Expression and regulation of sterol 27-hydroxylase (CYP27A1) in human macrophages: a role for RXR and PPARγ ligands. Biochem. J. 385 (2005) 823-830
140. Remaley A.T., Bark S., Walts A.D., Freeman L., Shulenin S., Annilo T., Elgin E., Rhodes H.E., Joyce C., Dean M., Santamarina-Fojo S., and Brewer Jr. H.B. Comparative genome analysis of potential regulatory elements in the ABCG5-ABCG8 gene cluster. Biochem. Biophys. Res. Commun. 295 (2002) 276-282
141. Repa J.J., and Mangelsdorf D.J. Nuclear receptor regulation of cholesterol and bile acid metabolism. Curr. Opin. Biotechnol. 10 (1999) 557-563
142. Repa J.J., Turley S.D., Lobaccaro J.A., Medina J., Li L., Lustig K., Shan B., Heyman R.A., Dietschy J.M., and Mangelsdorf D.J. Regulation of absorption and ABC1-mediated efflux of cholesterol by RXR heterodimers. Science 289 (2000) 1524-1529
143. Repa J.J., Liang G., Ou J., Bashmakov Y., Lobaccaro J.M., Shimomura I., Shan B., Brown M.S., Goldstein J.L., and Mangelsdorf D.J. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRα and LXRβ. Genes Dev. 14 (2000) 2819-2830
144. Repa J.J., Berge K.E., Pomajzl C., Richardson J.A., Hobbs H., and Mangelsdorf D.J. Regulation of ATP-binding cassette sterol transporters ABCG5 and ABCG8 by the liver X receptors alpha and beta. J. Biol. Chem. 277 (2002) 18793-18800
145. Rosen H., Reshef A., Maeda N., Lippoldt A., Shpizen S., Triger L., Eggertsen G., Björkhem I., and Leitersdorf E. Markedly reduced bile acid synthesis but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted sterol 27-hydroxylase gene. J. Biol. Chem. 273 (1998) 14805-14812
146. Rosen E.D., Sarraf P., Troy A.E., Bradwin G., Moore K., Milstone D.S., Spiegelman B.M., and Mortensen R.M. PPAR γ is required for the differentiation of adipose tissue in vivo and in vitro. Mol. Cell 4 (1999) 611-617
147. Rowe A.H., Argmann C.A., Edwards J.Y., Sawyez C.G., Morand O.H., Hegele R.A., and Huff M.W. Enhanced synthesis of the oxysterol 24(S), 25-epoxycholesterol in macrophages by inhibitors of 2,3-oxidosqualene:lanosterol cyclase: a novel mechanism for the attenuation of foam cell formation. Circ. Res. 93 (2003) 717-725
148. Russell D.W. Nuclear orphan receptors control cholesterol catabolism. Cell 97 (1999) 539-542
149. Russell D.W. Oxysterol biosynthetic enzymes. Biochim. Biophys. Acta 1529 (2000) 126-135
150. Rust S., Rosier M., Funke H., Real J., Amoura Z., Piette J.C., Deleuze J.F., Brewer H.B., Duverger N., Denefle P., and Assmann G. Tangier disease is caused by mutations in the gene encoding ATP-binding cassette transporter 1. Nat. Genet. 22 (1999) 352-355
151. Sabol S.L., Brewer Jr. H.B., and Santamarina-Fojo S. The human ABCG1 gene: identification of LXR response elements that modulate expression in macrophages and liver. J. Lipid Res. 46 (2005) 2151-2167
152. Schild R.L., Schaiff W.T., Carlson M.G., Cronbach E.J., Nelson D.M., and Sadovsky Y. The activity of PPAR γ in primary human trophoblasts is enhanced by oxidized lipids. J. Clin. Endocrinol. Metab. 87 (2002) 1105-1110
153. Schmidt R.J., Ficorilli J.V., Zhang Y., Bramlett K.S., Beyer T.P., Borchert K., Dowless M.S., Houck K.A., Burris T.P., Eacho P.I., Liang G., Guo L.W., Wilson W.K., Michael L.F., and Cao G. A 15-ketosterol is a liver X receptor ligand that suppresses sterol-responsive element binding protein-2 activity. J. Lipid Res. 47 (2006) 1037-1044
154. Schultz J.R., Tu H., Luk A., Repa J.J., Medina J.C., Li L., Schwendner S., Wang S., Thoolen M., Mangelsdorf D.J., Lustig K.D., and Shan B. Role of LXRs in control of lipogenesis. Genes Dev. 14 (2000) 2831-2838
155. Schwartz K., Lawn R.M., and Wade D.P. ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochem. Biophys. Res. Commun. 274 (2000) 794-802
156. Sevov M., Elfineh L., and Cavelier L.B. Resveratrol regulates the expression of LXR-α in human macrophages. Biochem. Biophys. Res. Commun. 348 (2006) 1047-1054
157. Shao W., and Brown M. Advances in estrogen receptor biology: prospects for improvements in targeted breast cancer therapy. Breast Cancer Res. 6 (2004) 39-52
158. Singh S.B., Ondeyka J.G., Liu W., Chen S., Chen T.S., Li X., Bouffard A., Dropinski J., Jones A.B., McCormick S., Hayes N., Wang J., Sharma N., Macnaul K., Hernandez M., Chao Y.S., Baffic J., Lam M.H., Burton C., Sparrow C.P., and Menke J.G. Discovery and development of dimeric podocarpic acid leads as potent agonists of liver X receptor with HDL cholesterol raising activity in mice and hamsters. Bioorg. Med. Chem. Lett. 15 (2005) 2824-2828
159. Skalen K., Gustafsson M., Rydberg E.K., Hulten L.M., Wiklund O., Innerarity T.L., and Boren J. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 417 (2002) 750-754
160. Song C., and Liao S. Cholestenoic acid is a naturally occurring ligand for liver X receptor α. Endocrinology 141 (2000) 4180-4184
161. Song C., Kokontis J.M., Hiipakka R.A., and Liao S. Ubiquitous receptor: a receptor that modulates gene activation by retinoic acid and thyroid hormone receptors. Proc. Natl. Acad. Sci. USA 91 (1994) 10809-10813
162. Song C., Hiipakka R.A., Kokontis J.M., and Liao S. Ubiquitous receptor: structures, immunocytochemical localization, and modulation of gene activation by receptors for retinoic acids and thyroid hormones. Ann. NY Acad. Sci. 761 (1995) 38-49
163. Song C., Hiipakka R.A., and Liao S. Selective activation of liver X receptor α by 6α-hydroxy bile acids and analogs. Steroids 65 (2000) 423-427
164. Song C., Hiipakka R.A., and Liao S. Auto-oxidized cholesterol sulfates are antagonistic ligands of liver X receptors: implications for the development and treatment of atherosclerosis. Steroids 66 (2001) 473-479
165. Sparrow C.P., Baffic J., Lam M.H., Lund E.G., Adams A.D., Fu X., Hayes N., Jones A.B., Macnaul K.L., Ondeyka J., Singh S., Wang J., Zhou G., Moller D.E., Wright S.D., and Menke J.G. A potent synthetic LXR agonist is more effective than cholesterol loading at inducing ABCA1 mRNA and stimulating cholesterol efflux. J. Biol. Chem. 277 (2002) 10021-10027
166. Spiteller G. Is atherosclerosis a multifactorial disease or is it induced by a sequence of lipid peroxidation reactions?. Ann. NY Acad. Sci. 1043 (2005) 355-366
167. Steffensen K.R., Schuster G.U., Parini P., Holter E., Sadek C.M., Cassel T., Eskild W., and Gustafsson J.A. Different regulation of the LXRα promoter activity by isoforms of CCAAT/enhancer-binding proteins. Biochem. Biophys. Res. Commun. 293 (2002) 1333-1340
168. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320 (1989) 915-924
169. Steinman R.M., Kaplan G., Witmer M.D., and Cohn Z.A. Identification of a novel cell type in peripheral lymphoid organs of mice. V. Purification of spleen dendritic cells, new surface markers, and maintenance in vitro. J. Exp. Med. 149 (1979) 1-16
170. Svensson S., Ostberg T., Jacobsson M., Norstrom C., Stefansson K., Hallen D., Johansson I.C., Zachrisson K., Ogg D., and Jendeberg L. Crystal structure of the heterodimeric complex of LXRα and RXRβ ligand-binding domains in a fully agonistic conformation. EMBO J. 22 (2003) 4625-4633
171. Svensson P.A., Hagg D.A., Jernas M., Englund M.C., Hulten L.M., Ohlsson B.G., Hulthe J., Wiklund O., Carlsson B., Fagerberg B., and Carlsson L.M. Identification of genes predominantly expressed in human macrophages. Atherosclerosis 177 (2004) 287-290
172. Szanto A., and Nagy L. Retinoids potentiate peroxisome proliferator-activated receptor γ action in differentiation, gene expression, and lipid metabolic processes in developing myeloid cells. Mol. Pharmacol. 67 (2005) 1935-1943
173. Szanto A., Benko S., Szatmari I., Balint B.L., Furtos I., Rühl R., Molnar S., Csiba L., Garuti R., Calandra S., Larsson H., Diczfalusy U., and Nagy L. Transcriptional regulation of human CYP27 integrates retinoid, peroxisome proliferator-activated receptor, and liver X receptor signaling in macrophages. Mol. Cell Biol. 24 (2004) 8154-8166
174. Talukdar S., and Hillgartner F.B. The mechanism mediating the activation of acetyl-coenzyme A carboxylase-α gene transcription by the liver X receptor agonist T0-901317. J. Lipid Res. 47 (2006) 2451-2461
175. Tamehiro N., Sato Y., Suzuki T., Hashimoto T., Asakawa Y., Yokoyama S., Kawanishi T., Ohno Y., Inoue K., Nagao T., and Nishimaki-Mogami T. Riccardin C: a natural product that functions as a liver X receptor (LXR)α agonist and an LXRβ antagonist. FEBS Lett. 579 (2005) 5299-5304
176. Tangirala R.K., Bischoff E.D., Joseph S.B., Wagner B.L., Walczak R., Laffitte B.A., Daige C.L., Thomas D., Heyman R.A., Mangelsdorf D.J., Wang X., Lusis A.J., Tontonoz P., and Schulman I.G. Identification of macrophage liver X receptors as inhibitors of atherosclerosis. Proc. Natl. Acad. Sci. USA 99 (2002) 11896-11901
177. Tarrade A., Schoonjans K., Guibourdenche J., Bidart J.M., Vidaud M., Auwerx J., Rochette-Egly C., and Evain-Brion D. PPARγ/RXRα heterodimers are involved in human CG β synthesis and human trophoblast differentiation. Endocrinology 142 (2001) 4504-4514
178. Tarrade A., Schoonjans K., Pavan L., Auwerx J., Rochette-Egly C., Evain-Brion D., and Fournier T. PPARγ/RXRα heterodimers control human trophoblast invasion. J. Clin. Endocrinol. Metab. 86 (2001) 5017-5024
179. Terasaka N., Hiroshima A., Koieyama T., Ubukata N., Morikawa Y., Nakai D., and Inaba T. T-0901317, a synthetic liver X receptor ligand, inhibits development of atherosclerosis in LDL receptor-deficient mice. FEBS Lett. 536 (2003) 6-11
180. Teupser D., Kretzschmar D., Tennert C., Burkhardt R., Wilfert W., Fengler D., Naumann R., Sippel A.E., and Thiery J. Effect of macrophage overexpression of murine liver X receptor-α (LXR-α) on atherosclerosis in LDL-receptor deficient mice. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 2009-2015
181. Tontonoz P., Hu E., Graves R.A., Budavari A.I., and Spiegelman B.M. MPPARγ2: tissue-specific regulator of an adipocyte enhancer. Genes Dev. 8 (1994) 1224-1234
182. Tontonoz P., Nagy L., Alvarez J.G., Thomazy V.A., and Evans R.M. PPARγ promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93 (1998) 241-252
183. Torra I.P., Ismaili N., Feig J.E., Xu C.F., Cavasotto C., Pancratov R., Rogatsky I., Neubert T.A., Fisher E.A., and Garabedian M.J. Phosphorylation of liver X receptor α selectively regulates target gene expression in macrophages. Mol. Cell Biol. 28 (2008) 2626-2636
184. Umetani M., Domoto H., Gormley A.K., Yuhanna I.S., Cummins C.L., Javitt N.B., Korach K.S., Shaul P.W., and Mangelsdorf D.J. 27-Hydroxycholesterol is an endogenous SERM that inhibits the cardiovascular effects of estrogen. Nat. Med. 13 (2007) 1185-1192
185. Unno A., Takada I., Takezawa S., Oishi H., Baba A., Shimizu T., Tokita A., Yanagisawa J., and Kato S. TRRAP as a hepatic coactivator of LXR and FXR function. Biochem. Biophys. Res. Commun. 327 (2005) 933-938
186. Uppenberg J., Svensson C., Jaki M., Bertilsson G., Jendeberg L., and Berkenstam A. Crystal structure of the ligand binding domain of the human nuclear receptor PPARγ. J. Biol. Chem. 273 (1998) 31108-31112
187. Valledor A.F., Hsu L.C., Ogawa S., Sawka-Verhelle D., Karin M., and Glass C.K. Activation of liver X receptors and retinoid X receptors prevents bacterial-induced macrophage apoptosis. Proc. Natl. Acad. Sci. USA 101 (2004) 17813-17818
188. Venkateswaran A., Repa J.J., Lobaccaro J.M., Bronson A., Mangelsdorf D.J., and Edwards P.A. Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J. Biol. Chem. 275 (2000) 14700-14707
189. Venkateswaran A., Laffitte B.A., Joseph S.B., Mak P.A., Wilpitz D.C., Edwards P.A., and Tontonoz P. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR α. Proc. Natl. Acad. Sci. USA 97 (2000) 12097-12102
190. Verschuren, L., de Vries-van der Weij, J., Zadelaar, S., Kleemann, R., Kooistra, T., 2008. LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in ApoE*3Leiden mice: time course and potential mechanisms. J. Lipid Res., Epub (August 30).
191. Wagner B.L., Valledor A.F., Shao G., Daige C.L., Bischoff E.D., Petrowski M., Jepsen K., Baek S.H., Heyman R.A., Rosenfeld M.G., Schulman I.G., and Glass C.K. Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression. Mol. Cell Biol. 23 (2003) 5780-5789
192. Wang Y., Kurdi-Haidar B., and Oram J.F. LXR-mediated activation of macrophage stearoyl-CoA desaturase generates unsaturated fatty acids that destabilize ABCA1. J. Lipid Res. 45 (2004) 972-980
193. Whitney K.D., Watson M.A., Goodwin B., Galardi C.M., Maglich J.M., Wilson J.G., Willson T.M., Collins J.L., and Kliewer S.A. Liver X receptor (LXR) regulation of the LXRα gene in human macrophages. J. Biol. Chem. 276 (2001) 43509-43515
194. Willy P.J., and Mangelsdorf D.J. Unique requirements for retinoid-dependent transcriptional activation by the orphan receptor LXR. Genes Dev. 11 (1997) 289-298
195. Willy P.J., Umesono K., Ong E.S., Evans R.M., Heyman R.A., and Mangelsdorf D.J. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 9 (1995) 1033-1045
196. Wong J., Quinn C.M., and Brown A.J. Statins inhibit synthesis of an oxysterol ligand for the liver x receptor in human macrophages with consequences for cholesterol flux. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 2365-2371
197. Wong J., Quinn C.M., and Brown A.J. Synthesis of the oxysterol, 24(S), 25-epoxycholesterol, parallels cholesterol production and may protect against cellular accumulation of newly-synthesized cholesterol. Lipids Health Dis. 6 (2007) 10
198. Wong J., Quinn C.M., Gelissen I.C., and Brown A.J. Endogenous 24(S), 25-epoxycholesterol fine-tunes acute control of cellular cholesterol homeostasis. J. Biol. Chem. 283 (2008) 700-707
199. Wrobel, J., Steffan, R., Bowen, S.M., Magolda, R., Matelan, E., Unwalla, R., Basso, M., Clerin, V., Gardell, S.J., Nambi, P., Quinet, E., Reminick, J.I., Vlasuk, G.P., Wang, S., Feingold, I., Huselton, C., Bonn, T., Farnegardh, M., Hansson, T., Nilsson, A.G., Wilhelmsson, A., Zamaratski, E., Evans, M.J., 2008. Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic triglyceride synthesis. J. Med. Chem., Epub (October 31).
200. Yoshikawa T., Shimano H., Amemiya-Kudo M., Yahagi N., Hasty A.H., Matsuzaka T., Okazaki H., Tamura Y., Iizuka Y., Ohashi K., Osuga J., Harada K., Gotoda T., Kimura S., Ishibashi S., and Yamada N. Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol. Cell Biol. 21 (2001) 2991-3000
201. Yu K., Bayona W., Kallen C.B., Harding H.P., Ravera C.P., McMahon G., Brown M., and Lazar M.A. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J. Biol. Chem. 270 (1995) 23975-23983
202. Yu L., Cao G., Repa J., and Stangl H. Sterol regulation of scavenger receptor class B type I in macrophages. J. Lipid Res. 45 (2004) 889-899
203. Zhang Y., Repa J.J., Gauthier K., and Mangelsdorf D.J. Regulation of lipoprotein lipase by the oxysterol receptors, LXRα and LXRβ. J. Biol. Chem. 276 (2001) 43018-43024
204. Zhu M., Fu Y., Hou Y., Wang N., Guan Y., Tang C., Shyy J.Y., and Zhu Y. Laminar shear stress regulates liver X receptor in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 28 (2008) 527-533